Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes

Vaccine

Volumn 13, Issue 14, 1995, Pages 1353-1359

  Levi, Raphael ^a   Aboud Pirak, Esther ^a   Leclerc, Claud ^b   Lowell, George H ^c   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b INSTITUT PASTEUR   (France)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Influenza; peptide synthetic vaccine; proteosomes; T and B epitopes

Indexed keywords

EPITOPE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; SYNTHETIC PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INTRANASAL DRUG ADMINISTRATION; MOUSE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMAL; B-LYMPHOCYTES; CHICK EMBRYO; EPITOPES; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA VACCINE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 0028806066     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(94)00083-Y     Document Type: Article

References (44)

1. Synthetic peptides as vaccines
2. New carriers and adjuvants in the development of vaccines
3. Liposomes as carriers of drugs. Observations on vesicle fate after injection and its control
4. The ISCOM: an immunostimulating complex
5. Proteosomes, hydrophobic anchors, ISCOMS, and liposomes for improved presentation of peptide and protein vaccines
6. Protection against group B Neisseria meningitides disease: preparation of soluble protein and protein-polysaccharide immunogens
7. Studies of porins spontaneously transferred from whole cells and Neisseria meningitides
8. Safety and antigenicity studies of a polyvalent meningococcal protein-polysaccharide vaccine
9. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants
10. Proteosomes-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides
11. The complex of flavivirus envelope polypeptide with meningococcal proteosomes elicits formation of virusneutralizing antibodies
12. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models
13. Influenza virus proteins: identity, synthesis, and modification analyzed by two-dimensional gel electrophoresis
14. The gene structure and replication of influenza virus
15. Structural basis of immune recognition of influenza virus hemagglutinin
16. Influenza
17. Immune responses to influenza virus in the mouse, and their role in control of the infection
18. Molecular mechanism of variation in influenza viruses
19. Anti-influenza response achieved by immunization with a synthetic conjugate
20. Synthetic vaccine against influenza with build-in adjuvanticity
21. Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice
22. Identification and characterization of T-helper epitopes in the nucleoprotein of influenza A virus
23. Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T-cells
24. d restricted T-cells
25. Identification of residues necessary for clonally specific recognition of cytotoxic T-cell determinant
26. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
27. Solid phase peptide synthesis II The synthesis of bradikinin
28. Growth purification and titration influenza viruses
29. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help
30. Use of moving averages and interpolation to estimate median-effective dose
31. The use of ranks to avoid the assumption of normality implicit in the analysis of variance
32. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity
33. Cytotoxic T-cells in the lungs of mice infected with an influenza A virus
34. The sensitization of mice with a wild-type and cold-adapted variant of influenza A virus. II. Secondary cytotoxic T cell responses
35. The immune response to influenza infection
36. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes
37. T helper cells
38. T cell-dependent B cell activation
39. T helper cells in cytotoxic T lymphocyte development: analysis of the cellular basis for deficient T helper cell function in the L3T4-independent T helper cell pathway
40. The priming of cytotoxic T-cell precursors is strictly helper T cell-dependent
41. Activated B cells can deliver help for the in vitro generation of antiviral cytotoxic T cells
42. An influenza haemagglutinin-specific IgG enhances class I MHC-restricted CTL killing in vitro
43. Hypothesis: immunological help is reciprocally delivered between different subpopulations of lymphocytes